Avid Bioservices - CDMO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.33
  • Forecasted Upside: 36.26%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$16.39
▲ +0.39 (2.44%)

This chart shows the closing price for CDMO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Avid Bioservices Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CDMO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CDMO

Analyst Price Target is $22.33
▲ +36.26% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Avid Bioservices in the last 3 months. The average price target is $22.33, with a high forecast of $25.00 and a low forecast of $20.00. The average price target represents a 36.26% upside from the last price of $16.39.

This chart shows the closing price for CDMO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Avid Bioservices. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/7/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/30/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2022StephensLower Target$22.00Low
12/7/2022Craig HallumLower Target$30.00 ➝ $25.00Low
12/7/2022Royal Bank of CanadaLower TargetOutperform$22.00 ➝ $20.00Low
6/30/2022Royal Bank of CanadaLower TargetOutperform$32.00 ➝ $22.00Low
3/9/2022Craig HallumLower Target$35.00 ➝ $30.00High
3/9/2022StephensLower TargetOverweight$31.00 ➝ $28.00High
12/8/2021Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$27.00 ➝ $32.00High
12/8/2021Craig HallumBoost TargetBuy ➝ Buy$29.00 ➝ $35.00High
6/30/2021Royal Bank of CanadaBoost TargetOutperform$21.00 ➝ $27.00High
6/30/2021Craig HallumBoost TargetBuy$21.00 ➝ $29.00High
6/30/2021KeyCorpBoost TargetPositive ➝ Overweight$22.00 ➝ $28.00High
3/16/2021Royal Bank of CanadaInitiated CoverageOutperform$21.00Medium
2/1/2021KeyCorpBoost Target$12.00 ➝ $22.00Low
11/9/2020KeyCorpInitiated CoverageOverweight$12.00Low
7/1/2020HC WainwrightReiterated RatingBuy$9.00Medium
3/11/2020HC WainwrightReiterated RatingBuy$11.00 ➝ $9.00High
12/10/2019HC WainwrightReiterated RatingBuy$11.00High
12/10/2019First AnalysisUpgradeOutperform ➝ Strong-Buy$7.50High
12/10/2019StephensBoost TargetOverweight$8.00 ➝ $10.00High
10/16/2019StephensInitiated CoverageOverweight$8.00High
10/16/2019Craig HallumInitiated CoverageBuy$11.00High
9/6/2019HC WainwrightSet TargetBuy$11.00High
7/8/2019HC WainwrightReiterated RatingBuy$11.00Low
6/28/2019HC WainwrightSet TargetBuy$11.00High
6/28/2019Janney Montgomery ScottUpgradeNeutral ➝ Buy$10.00High
5/9/2019Janney Montgomery ScottDowngradeBuy ➝ Neutral$10.00 ➝ $5.00High
12/11/2018HC WainwrightReiterated RatingBuy$11.00High
9/11/2018HC WainwrightBoost TargetBuy ➝ Buy$6.00 ➝ $11.00High
7/17/2018HC WainwrightReiterated RatingBuy$6.00High
6/25/2018Janney Montgomery ScottInitiated CoverageBuy$10.00High
5/24/2018HC WainwrightInitiated CoverageBuy$5.00High
3/15/2018Wells Fargo & CompanyInitiated CoverageOutperformHigh
3/13/2018First AnalysisInitiated CoverageOverweight$4.00Medium
(Data available from 1/29/2018 forward)

News Sentiment Rating

1.17 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/3/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/2/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/1/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/1/2022
  • 5 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/31/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/30/2022
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/30/2022
  • 6 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/29/2023

Current Sentiment

  • 6 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Avid Bioservices logo
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Read More

Today's Range

Now: $16.39
Low: $15.91
High: $16.49

50 Day Range

MA: $14.74
Low: $12.61
High: $17.23

52 Week Range

Now: $16.39
Low: $11.30
High: $22.83

Volume

416,649 shs

Average Volume

466,566 shs

Market Capitalization

$1.02 billion

P/E Ratio

9.70

Dividend Yield

N/A

Beta

1.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Avid Bioservices?

The following Wall Street research analysts have issued stock ratings on Avid Bioservices in the last twelve months: Craig Hallum, Royal Bank of Canada, Stephens, and StockNews.com.
View the latest analyst ratings for CDMO.

What is the current price target for Avid Bioservices?

3 Wall Street analysts have set twelve-month price targets for Avid Bioservices in the last year. Their average twelve-month price target is $22.33, suggesting a possible upside of 36.3%. Craig Hallum has the highest price target set, predicting CDMO will reach $25.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $20.00 for Avid Bioservices in the next year.
View the latest price targets for CDMO.

What is the current consensus analyst rating for Avid Bioservices?

Avid Bioservices currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CDMO will outperform the market and that investors should add to their positions of Avid Bioservices.
View the latest ratings for CDMO.

What other companies compete with Avid Bioservices?

How do I contact Avid Bioservices' investor relations team?

Avid Bioservices' physical mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company's listed phone number is (714) 508-6100 and its investor relations email address is [email protected] The official website for Avid Bioservices is www.avidbio.com. Learn More about contacing Avid Bioservices investor relations.